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Abstract
Platelet-derived growth factor (PDGF) was originally identified as a constituent of blood serum and
subsequently purified from human platelets. PDGF ligand is a dimeric molecule consisting of two
disulfide-bonded chains from A-, B-, C- and D-polypeptide chains, which combine to homo- and
heterodimers. The PDGF isoforms exert their cellular effects by binding to and activating two
structurally related protein tyrosine kinase receptors. PDGF is a potent mitogen and
chemoattractant for mesenchymal cells and also a chemoattractant for neutrophils and monocytes.
In radiation oncology, PDGF are important for several pathologic processes, including oncogenesis,
angiogenesis and fibrogenesis. Autocrine activation of PDGF was observed and interpreted as an
important mechanism involved in brain and other tumors. PDGF has been shown to be fundamental
for the stability of normal blood vessel formation, and may be essential for the angiogenesis in
tumor tissue. PDGF also plays an important role in the proliferative disease, such as atherosclerosis
and radiation-induced fibrosis, regarding its proliferative stimulation of fibroblast cells. Moreover,
PDGF was also shown to stimulate production of extracellular matrix proteins, which are mainly
responsible for the irreversibility of these diseases. This review introduces the structural and
functional properties of PDGF and PDGF receptors and discusses the role and mechanism of PDGF
signaling in normal and tumor tissues under different conditions in radiation oncology.
Background
PDGF was originally identified as a constituent of whole
blood serum that was absent in cell-free plasma [1,2] and
subsequently purified from human platelets [3,4].
Although the α-granules of platelets are a major storage
site for PDGF, recent studies have shown that PDGF can
be synthesized by a number of different cell types such as
macrophages, epithelial and endothelial cells [5-8]. Stud-
ies have shown that PDGF has important physiologic
functions in organ development [9,10]. PDGF has also
been implicated in a wide variety of pathological proc-
esses, including fibrosis, atherosclerosis, glomerulone-
phritis and aggressive fibromatosis [11-15]. Moreover,
aberrant production of PDGF and autocrine stimulation
may be an important mechanism in the neoplastic con-
version of PDGF receptor-positive cells [16-18]. Here, we
point out the most important features of PDGF and PDGF
receptors concerning their roles in radiation oncology.
PDGF structure and signaling
PDGF is a disulfide-linked dimer of two related polypep-
tide chains, designated A, B, C and D, which are assem-
bled as heterodimers (PDGF-AB) or homodimers (PDGF-
AA, PDGF-BB, PDGF-CC and PDGF-DD) [19-21]. PDGF
exerts its biological activity by binding to structurally sim-
ilar PDGF receptors (PDGFR-α and -β). The PDGFR-α
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binds to A-, B- and C- chains with high affinity, whereas
PDGFR-β only binds the B- and D- chains [22-25]. Differ-
ent from PDGF-A and -B, PDGF-C and PDGF-D require
proteolytic activation before binding to and activation of
PDGFR [19,20]. PDGF ligand dimer induces dimerization
of both receptors and subsequently autophosphorylation
of the PDGF receptor tyrosine kinase (RTK). Activated RTK
phosphorylates numerous signaling molecules that initi-
ate intracellular signaling cascades (Reviewed in Ref.
[31]).
The best characterized mechanisms by which PDGF
down-streaming signaling mediates cellular responses
involve the activation of the ras/MAPK pathway, which
can functionally increase cellular proliferation, migration
and differentiation [26], and the PI3K/Akt pathway,
which promotes cell survival [27]. Both pathways are of
crucial importance for tumor resistance to radiotherapy
and chemotherapy. Furthermore, platelet-derived growth
factor (PDGF) exerts its potent mitogen and chemotactic
effects in a variety of mesenchymal cells such as fibrob-
lasts, vascular smooth muscle cells, glomerular mesangial
cells, and brain glial cells [14,28-30] making PDGF a
potential key molecule for tissue rebuilding in response to
physiological and non-physiological conditions.
PDGF in oncology
Many investigators have shown that autocrine activation
of PDGF was interpreted to be an important pathogenetic
mechanism involved in different brain tumors [16-18].
In gliomas, analysis of PDGF/PDGFR expression sug-
gested the presence of autocrine and paracrine loops of
PDGF in glioma activating PDGFR-α in glioma cells,
while PDGFR-α expression was higher in malign gliomas
than in benign gliosis [17].
Moreover, the recently identified new PDGF isoforms,
PDGF-C and -D are also detectable in glioblastoma cell
lines and primary human tumor tissues [31].
On the other hand, treatment with a PDGFR antagonist
interrupted autocrine growth stimulation and thus inhib-
ited survival and mitogenesis in glioblastoma cells and
prevented glioma formation in a mouse xenograft model
[31,32].
In the case of meningioma, Adam and his colleagues pro-
vided evidence that cytokines secreted by meningioma
cells profoundly stimulated growth of meningioma and
neuroblastoma cells in vitro, while this growth stimula-
tion was completely abolished by a neutralizing antibody
against PDGF [16]. Todo et al showed DNA synthesis in
tumor cells could be inhibited through an antagonist of
PDGF in three of seven meningiomas cell lines [32].
Similarly, autocrine loops involving PDGF-A or -B and
their respective receptors was also observed in many
malignant and low-grade astrocytomas, while the activa-
tion of PDGF autocrine loops was suggested to be an early
event in the pathogenesis of malignant astrocytomas [33].
Aggressive fibromatosis also referred to as desmoid tumor
develops from muscle connective tissue, fasciae and
aponeuroses. The neoplasm is composed of fibrocyte-like
cells, and characterized by local infiltrative growth and
high risk of recurrence (~70%) after surgical treatment
[34]. Depending on the location and extent of the tumor,
radiotherapy is indicated for patients with unresectable
tumors or those with positive resection margins. Overex-
pression of PDGF were observed in desmoid tumors,
while inhibition of PDGF signaling by imatinib induced
overall 1 year tumor control rate of 36.8% in a phase II
clinical study [15]. Thus, inhibition of PDGF may be an
attractive therapy option, alone or combined with surgery
or/and radiotherapy in refractory cases.
Another example for an important role of PDGF in onco-
genesis is the so-called gastrointestinal stromal tumors
(GISTs). Many GISTs have gain-of-function mutations of
c-kit receptor tyrosine kinase (KIT) gene. Approximately
35% of GISTs lacking KIT mutations have intragenic acti-
vation mutations in PDGFR-α [35].
However, the alternative defects lead to similar alterations
of the downstream signaling cascades and cytogenetic
changes. Therefore the defects (gain-of-function through
mutated-KIT or mutated-PDGFR-α) appear to be alterna-
tive and mutually exclusive [35].
Likewise, overexpression of PDGF and c-kit was also
observed in Leydig tumors. Treatment with imatinib
almost completely inhibited Leydig tumor growth in an
allograft mouse model by inhibition of PDGF and c-kit
signaling with no drug-resistance development during
imatinib treatment [36].
The clinical success of imatinib/gleevec, a triple tyrosine
kinase inhibitor of c-kit, PDGF and c-Abl signaling, in
chronic myeloid leukemia [37] and gastrointestinal stro-
mal tumors [38] has accelerated the development of
molecular targeted cancer therapy. It is highly likely that
many more antitumoral substances of this class will be
developed and discovered in the near future.
PDGF and angiogenesis
In addition to its direct tumor growth promoting effect,
the importance of PDGF in tumor propagation relates to
the inherent angiogenic activity [39]. In this regard, PDGF
has been shown to be essential for the stability of normal
blood vessel formation by recruiting pericytes andRadiation Oncology 2007, 2:5 http://www.ro-journal.com/content/2/1/5
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smooth muscle cells [40]. PDGF-B expression by endothe-
lial cells recruits pericytes through a short-range paracrine
mode [41]. Pericytes expressing PDGFRs migrate along
steep gradient of PDGF-B in the peri-endothelial compart-
ment to endothelial cells and thus initiate intimate asso-
ciation with the abluminal surface of the endothelial cells
[41]. Pericyte-deficiency promotes a range of microvascu-
lar changes, such as endothelial hyperplasia, vessel dila-
tion, leakage and rupture, leading to capillary
microaneurysms, and lethal microhemorrhage [40].
Despite structural and functional abnormalities in the
microvasculature, mice embryos deficient of up to 90%
pericytes are compatible with embryonic and postnatal
survival, while loss of more than 95% of the pericytes is
lethal [40,42]. This suggests that a rather low threshold
density of pericytes is required for basal microvascular
function.
Angiogenesis is an important event in tumor growth, since
tumors located more than 100–200 μm distant from a
blood vessel need neovascular formation to ensure a suf-
ficient supply of nutrients and oxygen [43]. Tumor cells in
hypoxia secrete cytokines, including VEGF, PDGF, basic
fibroblast growth factor (bFGF), insulin growth factor
(IGF), to stimulate neovascular formation [43].
However, neovasculature in tumors differs strikingly from
normal physiologic vessels. The badly coordinated growth
leads to vessel malformation including vessel dilation,
tortuosity, leakage, rupture and formation of microaneu-
rysms [40]. Interestingly, these hallmarks of microvascu-
lar malformation in tumors were found to be identical
with the alterations found in pericyte-deficient mice
(PDGF-B -/- or PDGFR-β -/-), pointing to a pericyte-defi-
ciency in the disordered neovascular formation in tumors
[41].
Since small numbers of pericytes in tumor vessels may be
critical for vessel integrity and function [40], targeting per-
icytes in tumors may be an attractive and efficacious way
for anti-angiogenic therapy.
Recent data from experiments in vivo imply that targeting
pericytes actually provides additional benefits [44]. Tradi-
tionally, endothelial cells as a host component in the
tumors with normal genome are suggested to be the pri-
mary target for anti-angiogenic therapies [45]. Inhibiting
VEGF in endothelial cells reduced endothelial cell sur-
vival, proliferation, tube formation and invasion in vitro
[45]. However, Erber and his colleagues demonstrated
that endothelial cells were resistant to the inhibitory effect
of SU5416 by blocking VEGFR in vivo through pericyte
mediated escape strategies via the Ang-1/Tie2 pathway
[46]. Combined inhibition of VEGF and PDGF signaling
enforces tumor vessel regression by direct anti-angiogenic
effect to endothelial cells and pericytes and by inhibiting
pericyte mediated endothelial cell survival mechanisms
[46].
This view is also supported by other studies showing that
tumor vessels lacking pericytes are more dependent on
VEGF for their survival than are vessels invested by peri-
cytes [44]. In fact, sorafenib and sunitinib/SU11248 act as
anti-angiogenic agents by inhibiting VEGFR-2/-3, PDGFR-
β, Flt-3, and c-KIT. Both drugs exert clear clinical effects in
patients with renal cell carcinoma which are most likely
mediated via anti-angiogenic effects [47,48]. The thera-
peutic efficacy to other tumors is currently under investi-
gation [48].
In conclusion, PDGF has at least two distinct functions in
pro-angiogenic signaling. On the one hand PDGF
increases survival and proliferation of endothelial cells
and on the other hand, PDGF regulates vessel growth via
pericyte recruitment and association to newly formed ves-
sels.
PDGF inhibition in combination with 
radiotherapy
Ionising radiation causes miscellaneous effects to the
tumor mass. It exerts a direct antitumoral effect on tumor
cells, for example through DNA double-strand-break lead-
ing to failure of DNA transcription and duplication and
eventual death of tumor cells [49]. However, radiation
induced damage of endothelial cells plays a major role in
tissue damage and antitumoral efficacy [45]. In this
regard, within hours after ionising radiation, lesions with
structural changes could be observed in endothelial cells
by using electron microscopy [50]. Thus, ionising radia-
tion can be also considered as a potent anti-angiogenic
agent [45].
On the other hand, it was shown that tumor cells are able
to produce pro-angiogenic cytokines including VEGF,
PDGF and FGF in response to ionising radiation. These
pro-angiogenic cytokines could protect endothelial cells
and vessels from radiation-induced damage and conse-
quently ensure supply of oxygen and nutrients for tumor
cells [9,11,18]. The secretion of PDGF could also be stim-
ulated in irradiated stromal cells, such as endothelial and
fibroblast cells [51]. Elevated expression of these growth
factors correlates with higher vessel density and negative
clinically prognosis in various tumors [52]. Usually, such
tumors possess a relative resistance to radiation therapy
[53].
Inhibition of pro-angiogenic signaling by tyrosine kinase
inhibitors can therefore augment the radiation induced
damage to endothelial cells and abolishes the tumor cells
mediated protection. Moreover, these inhibitors can pre-Radiation Oncology 2007, 2:5 http://www.ro-journal.com/content/2/1/5
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vent the re-growth of endothelial cells and neovascular
formation.
Consequently, anti-angiogenic substances targeting VEGF
and PDGF may increase anti-angiogenic activity of ionis-
ing radiation and possess a potent antitumoral synergy
with radiation.
Glioma is a good example for demonstration of the dual
role of PDGF signaling in the oncogenesis and angiogen-
esis in tumor mass.
Using in situ hybridization and immunohistochemistry
techniques, Hermanson et al demonstrated the presence
of autocrine and paracrine loops in gliomas, activating the
PDGFR-α in glioma cells. The activation of PDGFR-β in
endothelial cells was also observed in the tumor mass,
pointing to the dual role of PDGF signaling in oncogene-
sis and angiogenesis in glioma tumors [17].
On the one hand, treatment with imatinib/gleevec dis-
rupted an autocrine PDGF/PDGFR loop by specifically
inhibiting phosphorylation of PDGFR and thus exerted a
synergistic antitumoral effect with ionising radiation as
radiosensitizer [54]. And on the other hand, targeting
PDGF signaling inhibits the hypoxia-induced angiogen-
esis and strengthens the anti-angiogenic effect of radiation
[46].
PDGF in radiotherapy-induced fibrogenesis
The development of acute inflammation and chronic
fibrosis is a frequent side effect of ionising radiation and
thus a dose-limiting factor for treatment efficacy [55].
In the case of lung tumors, the dose limitation imposed by
normal tissue tolerance presently precludes successful
radiotherapeutic treatment in many patients [56]. Pulmo-
nary fibrosis is a progressive condition, characterized by
mesenchymal cell proliferation, the subsequent deposi-
tion of extracellular matrix proteins and extensive remod-
eling of the pulmonary parenchyma [57]. In both human
and animal model systems, acute pneumonitis and late
fibrosis are directly dependent upon total irradiation
dose, fraction size, and lung volume irradiated [58-60].
New precise radiotherapy techniques can spare more nor-
mal tissue around tumor volume and thus reduce the
intensity of side effects. However a recent study has shown
that 14.6 % patients with lung cancer still developed inter-
mediate grade radiogenic pneumonitis after primary radi-
otherapy with dose escalation using 3D conformal
techniques and 13.8 % patients developed fibrosis [61].
The treatment of fibrosis remains still elusive, since the
exact mediators and mechanisms involved in fibrogenesis
are not completely understood [57]. The traditional inter-
pretation of radiation-induced fibrosis as a consequence
of acute inflammation has been questioned in recent
years, because clinical measures of inflammation do not
correlate well with fibrotic progression and because anti-
inflammatory drugs do not significantly affect clinical
outcome [56,62,63]. New evidence suggests that immedi-
ate intercellular communications through regulation of
cytokines happens within hours to days after irradiation
[64].
A number of investigations provided clear evidence for
increased expression of various cytokines including
PDGF, transforming growth factor-β, tumor necrosis fac-
tor-α and interleukin-1 in response to ionising radiation
[22,65-67]. In this regard, some pro-inflammatory
cytokines seem to be important for the acute impairment
in the pneumonitis phase, for example TNF-α and CD95-
ligand [66,68], whereas others are involved in the regula-
tion of the fibrotic response. For the development of
fibrosis, transforming growth factor-β is till now a widely
accepted key player [69].
Moreover, recent evidence supports an important role of
PDGF for the development of lung fibrosis in response to
ionising radiation. Firstly, PDGF and PDGFR are
expressed at low levels in normal adults, while elevated
levels are detected in lungs of patients with radiation-
induced pulmonary fibrosis [70]. Augmented expression
of PDGF is further observed in asbestos-, bleomycin- and
idiopathic pulmonary fibrosis [71-73]. Increased expres-
sion of PDGF in rat lungs by adenoviral delivery or lung-
specific over-expression in mice is associated with pro-
nounced lung fibrosis [74,75]. Moreover, inhibiting the
PDGF pathway with neutralising antibodies to PDGF or
administration of soluble extracellular region of PDGFR-
β could attenuate fibrotic development [76,77].
Recently it has been shown that three distinct receptor
tyrosine kinase inhibitors (RTKI), overlapping in inhibi-
tion of PDGF signaling, attenuated radiation-induced pul-
monary fibrogenesis in vivo [78]. The radiation-induced
overexpression of PDGF led to phosphorylation and acti-
vation of PDGFR in lungs of irradiated mice, while the
phosphorylation of PDGFR was strongly inhibited in both
irradiated groups treated with RTKIs. Accordingly, the
treatment with RTKIs attenuated the development of pul-
monary fibrosis in excellent correlation with clinical, his-
tological, and computed tomography results, although
the acute inflammatory response induced by radiation
injury was not completely abrogated. Moreover, all three
tyrosine kinase inhibitors reduced lung fibrosis after radi-
ation injury and prolonged animal survival. Thus, there is
hard evidence to support the important role of the PDGF/
PDGFR system for mesenchymal cells in proliferative dis-
eases.Radiation Oncology 2007, 2:5 http://www.ro-journal.com/content/2/1/5
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Schematic presentation of radiation induced fibrogenesis in lungs Figure 1
Schematic presentation of radiation induced fibrogenesis in lungs. Illustration of a microenvironment of gas-blood exchange 
unit in lungs in the physiologic conditions (upper part) and radiation induced activation of PDGF pathways in the fibrogenesis in 
lungs (lower part).
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Since fibroblasts are the putative effector cells, recruitment
and stimulation of fibroblasts should be the most impor-
tant event during development of fibrosis. In this regard,
PDGF may exert profibrotic effect through its mitogenic
and chemotactic stimulation to mesenchymal cells, such
as fibroblasts, myofibroblasts and smooth muscle cells
[79]. Moreover, PDGF was also shown to stimulate pro-
duction of extracellular matrix proteins, such as collagen,
hyaluronic acid, fibronectin and proteoglycan [80-83],
which are mainly responsible for the irreversibility of
fibrotic lesion.
The radiation-induced secretion of PDGF has been
assumed to derive solely from leucocytes. However, radi-
ation of stromal cells, such as fibroblasts and endothelial
cells, induced paracrine PDGF in co-culture systems
which substantially stimulated the proliferation of non-
irradiated fibroblasts [51].
In accordance with these results, endothelial cells were
reported as potential sources of PDGF after radiation in
vitro [84]. Moreover, the expression of c-sis mRNA in epi-
thelial cells was also observed in certain pulmonary
fibrotic diseases [85].
Other experiments demonstrated that anti-inflammatory
treatment with dexamethasone did not decrease the level
of PDGF-BB or the mitogenic activity of bronchial alveo-
lar lavage fluid for fibroblasts in the chronic lung disease
of prematurity [86]. Savikko and his colleagues also
showed that limiting the extent of inflammation by
cyclosporin A treatment did not inhibit the expression of
PDGF ligands and receptors [87]. Thus, stromal cells, such
as endothelial, fibroblasts cells, should be at least partially
responsible for the release of cytokines, including PDGF.
A schematic diagram depicts the suggested role of radia-
tion induced PDGF signaling in fibrogenesis (Fig. 1).
Conclusion and outlook
PDGF signaling plays an important role in radiation
oncology with respect to its oncogenic, angiogenic and
profibrotic effects. The rational of targeting PDGF signal-
ing in radiation oncology can arise in three ways: 1) the
direct antitumoral potential, 2) the anti-angiogenic
impact, and 3) the antifibrotic activity which protects nor-
mal tissue from the side effects of ionising radiation.
Suppression of PDGF is discussed as one potential mech-
anism of action of some novel antifibrotic drugs undergo-
ing clinical trials [88,89]. It has been suggested that
pirfenidone and interferon gamma, both ameliorate lung
fibrosis by downregulation of PDGF expression [72,90].
However, since diverse signaling pathways activated by
growth factor receptors induce broadly overlapping,
rather than independent sets of signaling, it's unlikely to
completely inhibit a biologic process by blocking a single
cytokine/growth factor. Thus multi-targeted agents may
be more effective in the oncological therapy.
At the same time, a special attention should be paid to the
side effects of this new class of molecular targeted agents,
since clinical experience is still sparse, especially in com-
bination with radiotherapy and chemotherapy.
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